Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"

被引：0
|
作者：
Zubiaur, Pablo [1 ]
Leeder, J. Steven [2 ,3 ]
Abad-Santos, Francisco [1 ,4 ]
Gaedigk, Andrea [2 ,3 ]
机构：
[1] Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IP, Inst Teofilo Hernando, Clin Pharmacol Dept,Hosp Univ La Princesa, Madrid, Spain
[2] Childrens Mercy Res Inst CMRI, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA
[3] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64110 USA
[4] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷 / 02期
关键词：
D O I：
10.1002/cpt.3093
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [31] CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects
    Holstein, Andreas
    Beil, Winfried
    Kovacs, Peter
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (12) : 1549 - 1563
  • [32] Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians
    G Suarez-Kurtz
    J P Genro
    M O de Moraes
    E B Ojopi
    S D J Pena
    J A Perini
    A Ribeiro-dos-Santos
    M A Romano-Silva
    I Santana
    C J Struchiner
    The Pharmacogenomics Journal, 2012, 12 : 267 - 276
  • [33] Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
    Miners, JO
    Coulter, S
    Birkett, DJ
    Goldstein, JA
    PHARMACOGENETICS, 2000, 10 (03): : 267 - 270
  • [34] Effects of herbalteas on CYP1A, CYP2C and CYP2D-mediated metabolic activities
    Nishimura, Yuki
    Kurata, Norimitsu
    Iwase, Mariko
    Yasuhara, Hajime
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 209P - 209P
  • [35] CYP2C and IL-6 expression in breast cancer
    Knüpfer, H
    Schmidt, R
    Stanitz, D
    Brauckhoff, M
    Schönfelder, M
    Preiss, R
    BREAST, 2004, 13 (01): : 28 - 34
  • [36] The incidence of genetic polymorphisms of CYP2C in a Korean population.
    Ko, JW
    Macpherson, AS
    Jang, IJ
    Shin, SG
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PIV24 - PIV24
  • [37] CLINICAL RELEVANCE OF GENETIC POLYMORPHISM OF THE CYP2C SUBFAMILY AND ITS EFFECT ON THE PHARMACOKINETICS IN CHILDREN WITH EPILEPSY
    Cvitanovic-Sojat, L.
    Malenica, M.
    Gjergja, Juraski R.
    EPILEPSIA, 2010, 51 : 68 - 68
  • [38] Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians
    Suarez-Kurtz, G.
    Genro, J. P.
    de Moraes, M. O.
    Ojopi, E. B.
    Pena, S. D. J.
    Perini, J. A.
    Ribeiro-dos-Santos, A.
    Romano-Silva, M. A.
    Santana, I.
    Struchiner, C. J.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (03): : 267 - 276
  • [39] The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma
    Wang, Xiangkun
    Yu, Tingdong
    Liao, Xiwen
    Yang, Chengkun
    Han, Chuangye
    Zhu, Guangzhi
    Huang, Ketuan
    Yu, Long
    Qin, Wei
    Su, Hao
    Liu, Xiaoguang
    Peng, Tao
    CANCER MEDICINE, 2018, 7 (04): : 966 - 980
  • [40] Induction of CYP2C genes in human hepatocytes in primary culture
    Gerbal-Chaloin, S
    Pascussi, JM
    Pichard-Garcia, L
    Daujat, M
    Waechter, F
    Fabre, JM
    Carrère, N
    Maurel, P
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (03) : 242 - 251
12345